Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

USP17L4 Inhibitors

USP17L4 inhibitors are a class of chemical compounds designed to specifically inhibit the activity of the ubiquitin-specific peptidase 17-like protein 4 (USP17L4). USP17L4 is a member of the deubiquitinating enzyme (DUB) family, which plays a critical role in the regulation of ubiquitin signaling by removing ubiquitin molecules from target proteins. Ubiquitination is a post-translational modification that can alter the stability, localization, or activity of proteins, and it is involved in a wide range of cellular processes including protein degradation, signal transduction, and DNA repair. USP17L4, like other DUBs, functions to precisely control these processes by reversing ubiquitination, thus modulating the fate and function of its substrate proteins. Inhibiting USP17L4 can disrupt these regulatory mechanisms, leading to alterations in cellular pathways that are dependent on ubiquitin signaling. The development and study of USP17L4 inhibitors involve detailed biochemical and structural investigations to understand how these compounds interact with the enzyme's active site and inhibit its deubiquitinating activity. Researchers typically use a variety of techniques, including X-ray crystallography, molecular modeling, and enzymatic assays, to design and optimize inhibitors that are specific to USP17L4. By blocking the activity of USP17L4, scientists can explore the specific functions of this enzyme in various cellular contexts, such as its role in controlling protein turnover, regulating signal transduction pathways, or maintaining cellular homeostasis. Additionally, USP17L4 inhibitors serve as important tools for studying the broader implications of deubiquitination in cellular regulation, providing insights into how the balance of ubiquitination and deubiquitination is maintained and how disruptions in this balance can affect cellular function. Through these studies, researchers aim to deepen their understanding of the complex networks governed by ubiquitin signaling and the critical role of DUBs like USP17L4 in these processes.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Cycloheximide

66-81-9sc-3508B
sc-3508
sc-3508A
100 mg
1 g
5 g
$40.00
$82.00
$256.00
127
(5)

Cycloheximide inhibits protein biosynthesis in eukaryotic organisms, potentially reducing USP17L4 synthesis.

Triptolide

38748-32-2sc-200122
sc-200122A
1 mg
5 mg
$88.00
$200.00
13
(1)

Triptolide represses transcriptional activity, which may lead to decreased USP17L4 mRNA production.

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$56.00
$260.00
$980.00
163
(3)

MG-132 inhibits the proteasome, leading to a feedback decrease in ubiquitin-proteasome system components, possibly including USP17L4.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$73.00
$238.00
$717.00
$2522.00
$21420.00
53
(3)

Actinomycin D binds to DNA and inhibits RNA polymerase, which could decrease USP17L4 mRNA transcription.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin inhibits mTOR, a kinase involved in the regulation of protein synthesis, potentially reducing USP17L4 expression.

Chloroquine

54-05-7sc-507304
250 mg
$68.00
2
(0)

Chloroquine disrupts lysosome function, which may alter cellular homeostasis and lead to reduced USP17L4 expression.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Bortezomib inhibits the proteasome, leading to altered protein turnover and potentially lower USP17L4 levels.

Mitomycin C

50-07-7sc-3514A
sc-3514
sc-3514B
2 mg
5 mg
10 mg
$65.00
$99.00
$140.00
85
(5)

Mitomycin C crosslinks DNA, which may inhibit transcription and result in decreased USP17L4 mRNA levels.

Epoxomicin

134381-21-8sc-201298C
sc-201298
sc-201298A
sc-201298B
50 µg
100 µg
250 µg
500 µg
$134.00
$215.00
$440.00
$496.00
19
(2)

Epoxomicin is a proteasome inhibitor that could lead to a compensatory reduction in USP17L4 expression.

Camptothecin

7689-03-4sc-200871
sc-200871A
sc-200871B
50 mg
250 mg
100 mg
$57.00
$182.00
$92.00
21
(2)

Camptothecin inhibits topoisomerase I, leading to DNA damage responses that could decrease USP17L4 transcription.